---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-25-000018"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:44:02.316491+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio FY2024 net loss $61.1M; cash runway into 2027; VTP-1000 data Q3 2025

## Summary
- Net loss of $61.1M ($1.55 per share) vs $73.3M in 2023; goodwill impairment of $12.2M.
- Cash $112.4M at Dec 31, 2024, down from $142.1M; expected cash runway into 2027.
- Revenue $15.0M from Vaxzevria royalties (no future payments expected).
- Lead candidate VTP-1000 (celiac disease) Phase 1 AVALON trial; single ascending dose data expected Q3 2025.
- VTP-300 for CHB achieved 8 participants with HBsAg loss, 2 functional cures; Phase 2b data due Q2 2025.

## SEC filing metadata
- accession: 0001828185-25-000018
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000018/0001828185-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000018/brns-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-25-000018
- JSON: https://secwatch.observer/filing/0001828185-25-000018.json
- Plain text: https://secwatch.observer/filing/0001828185-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.